Does Dipyridamole Have Antithrombotic Potential?

• References

• 1 Editorial. Doubts about dipyridamole as an antithrombotic drug. Drug Therapeut Bull 1984; 22: 25-28
• 2 Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement: a preliminary report. N Engl J Med 1968; 279: 576-580
• 3 Sullivan JM, Harken DE, Gorlin R. Effect of dipyridamole on the incidence of arterial emboli after cardiac valve replacement. Circulation 1969; 39 suppl (Suppl. 01) 149-153
• 4 Sullivan JM, Harken DE, Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med 1971; 284: 1391-1394
• 5 Broekmans AW, Loeliger EA. Therapeutic control of anticoagulant treatment. Br Med J 1982; 284: 1330-1331
• 6 Chesebro JH, Fuster V, Elveback LR, McGoon DC, Pluth JR, Puga FJ, Wallace RB, Danielson GK, Orszulak TA, Piehler JM, Schaff HV. Trial of combined warfarin plus dipyridamole or aspirin therapy in prosthetic heart valve replacement: danger of aspirin compared with dipyridamole. Am J Cardiol 1983; 51: 1537-1541
• 7 Marcus AJ. Aspirin as an antithrombotic medication. N Engl J Med 1983; 309: 1515-1516
• 8 Chesebro JH, Fuster V, Elveback LR, Clements IP, Smith HC, Holmes DR, Bardsley WT, Pluth JR, Wallace RB, Puga FJ, Orszulak TA. Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-214
• 9 Lorenz RL, Weber M, Kotzur J, Theisen K, Schacky CV, Meister W, Reichardt B, Weber PC. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Effects on platelet aggregation and thromboxane formation Lancet 1984; 1: 1261-1264
• 10 Lubsen J. Effect of anti-thrombotic therapy on bypass graft patency: evidence from a non-randomized study. IXth European Congress of Cardiology. Düsseldorf. 1984